RDG Share Price Performance
zł4.86
-0.34 (-6.54%)
Price zł4.86
Share Pricen/a
Read-Gene S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
RDG Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Read-Gene S.A. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 12, 2026
- 0.17
- 94.70%
- 11.79%
- 266.3%
About RDG
- Founded
- 2005
- Employees
- 20
- CEO
- WebsiteView website
Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. The chemoprevention segment engages in the use of natural or synthetic substances to inhibit, reverse, or delay the process of cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic oncology consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. It also operates an online platform. The company was incorporated in 2005 and is based in Dobra, Poland. Read-Gene S.A. is a subsidiary of Gen-Pat-Med Sp. z o.o.
